Comparing a new bone drug (SAL023) to Evenity in healthy volunteers
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This trial tests a new medicine called SAL023 to see how it compares to an approved drug (Evenity) in healthy people. It looks at how the body processes the drug, safety, and immune response. You must be healthy, within a certain age and weight range, and not have any bone or heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy Chinese man or woman between 18 and 45 years old.
- You weigh at least 50 kg and have a BMI between 19 and 25.
- You have no serious allergies, fractures in the last 6 months, or heart problems like a heart attack or stroke.
- You have not taken certain bone medications (like bisphosphonates) in the last year or any prescription drugs in the last 4 weeks.
- You do not smoke more than 5 cigarettes a day, drink more than 14 units of alcohol per week, or use illegal drugs.
- You and your partner agree to avoid pregnancy and not donate sperm or eggs during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
This trial is testing a medicine called romosozumab to treat postmenopausal women with severe osteoporosis and a recent fracture. It aims to find the best way to use this drug to strengthen bones and prevent more fractures.
This study looks at how well and how safely another osteoporosis medicine works for people who have already taken denosumab for 2 years. It may help find the best next step to strengthen bones and lower fracture risk after denosumab.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
This study tests a new injectable medication called SAL056 to strengthen bones and prevent fractures in postmenopausal women with osteoporosis. Researchers want to find the best dose and how often to give it.
This trial tests a new drug called SAL0167 in healthy people to see if it is safe and how the body processes it. The study has two parts: Part A includes all healthy volunteers, and Part B focuses on people with moderately high cholesterol.
Hear when a new Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.